{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:38:35Z","timestamp":1766579915551,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.nefroe.2020.11.011","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:51:31Z","timestamp":1620762691000},"page":"123-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group"],"prefix":"10.1016","volume":"41","author":[{"given":"Aleix","family":"Cases","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jes\u00fas","family":"Puchades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Martin-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Gorriz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2020.11.011_bib0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","article-title":"Anemia of chronic kidney disease: treat it, but not too aggressively","volume":"83","author":"Nakhoul","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.ki.5000105","article-title":"Association of anemia with outcomes in men with moderate and severe chronic kidney disease","volume":"69","author":"Kovesdi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/j.ajkd.2009.10.043","article-title":"Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD","volume":"55","author":"Stancu","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004","volume":"4","author":"Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0030","doi-asserted-by":"crossref","unstructured":"Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, et al. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kid J. sfz091, https:\/\/doi.org\/10.1093\/ckj\/sfz091.","DOI":"10.1093\/ckj\/sfz091"},{"issue":"1","key":"10.1016\/j.nefroe.2020.11.011_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfz192","article-title":"Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease","volume":"36","author":"Awan","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0045","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2019.04.029","article-title":"An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic veterans with predialysis chronic kidney disease","volume":"96","author":"Cho","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0050","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0060","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"Suppl 2","author":"Kidney disease: Improving Global Outcomes (KDIGO) Working Group","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0065","unstructured":"NICE guideline [NG8]: Chronic kidney disease: managing anaemia. Published date: June 2015. https:\/\/www.nice.org.uk\/guidance\/ng8."},{"key":"10.1016\/j.nefroe.2020.11.011_bib0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure. An overview","volume":"7","author":"von Haehling","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0075","first-page":"29","article-title":"Ferroterapia en el paciente con enfermedad renal cr\u00f3nica: entendiendo el estudio FIND-CKD","volume":"7","author":"Cases","year":"2016","journal-title":"Nefrolog\u00eda Sup Ext"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0080","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0085","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1537-2995.2011.03495.x","article-title":"Iron deficiency syndromes and iron-restricted erythropoiesis (CME)","volume":"52","author":"Goodnough","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0090","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2215\/CJN.02190309","article-title":"Hepcidin for clinicians","volume":"4","author":"Young","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0095","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","article-title":"KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD","volume":"62","author":"Kliger","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0110","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1681\/ASN.2010020173","article-title":"Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients","volume":"22","author":"Goodkin","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0120","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0125","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ndt\/gfv293","article-title":"A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia","volume":"31","author":"Kalra","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"author":"Higgins","key":"10.1016\/j.nefroe.2020.11.011_bib0135"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0140","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0145","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"2","author":"O\u2019Lone","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5414\/CN109198","article-title":"Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial","volume":"88","author":"Macdougall","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.nefroe.2020.11.011_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0165","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2015-05-642223","article-title":"Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice daily doses in iron-depleted young women","volume":"126","author":"Moretti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0170","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(17)30182-5","article-title":"Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron depleted women: two open-label, randomised controlled trials","volume":"4","author":"Stoffel","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nefro.2016.05.008","article-title":"Gut microbiota in chronic kidney disease","volume":"37","author":"Cigarran Guldris","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0180","first-page":"S28","article-title":"Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD","volume":"21 Suppl 1","author":"Kortman","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0185","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040098","article-title":"Gut microbiota and iron: the crucial actors in health and disease","volume":"11","author":"Yilmaz","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0190","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0200","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/jcpt.12281","article-title":"Heme iron polypeptide for the management of anaemia of chronic kidney disease","volume":"40","author":"Dull","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0210","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0215","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: a Prespecified Secondary Analysis of the PIVOTAL trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"JASN"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Conference Participants. Iron management in chronic kidney disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0225","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.amjmed.2012.01.015","article-title":"Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study","volume":"125","author":"Rostoker","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0230","first-page":"68","article-title":"Liver and cardiac iron deposition in patients on maintenance hemodialysis by magnetic resonance imaging T2","volume":"10","author":"Tolouian","year":"2016","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0235","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/nep.12735","article-title":"Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis","volume":"22","author":"Holman","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0240","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ebiom.2018.11.020","article-title":"Liver iron load influences hepatic fat fraction in end-stage renal disease patients on dialysis: a proof of concept study","volume":"39","author":"Rostoker","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0245","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of intravenous iron in dialysis a systematic review and meta-analysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000486968","article-title":"Positive iron balance in chronic kidney disease: how much is too much and how to tell?","volume":"47","author":"Wish","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0255","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0260","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/heartjnl-2014-305669","article-title":"Iron deficiency: an emerging therapeutic target in heart failure","volume":"100","author":"Cohen-Solal","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0265","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0270","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0275","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","article-title":"Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status","volume":"15","author":"Com\u00edn-Colet","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0285","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","article-title":"Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure","volume":"35","author":"Jankowska","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0290","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0295","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","article-title":"Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial","volume":"15","author":"Filippatos","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0305","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ejhf.229","article-title":"The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study","volume":"17","author":"Ponikowski","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0315","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.hlc.2014.12.161","article-title":"Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron","volume":"24","author":"Toblli","year":"2015","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0320","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ehf2.12101","article-title":"Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study","volume":"3","author":"N\u00fa\u00f1ez","year":"2016","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0325","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014254","article-title":"Noninvasive imaging estimation of myocardial iron repletion following administration of intravenous iron: the myocardial-IRON trial","volume":"9","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0330","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials","volume":"18","author":"Jankowska","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0335","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0340","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0345","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0350","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0355","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ejhf.84","article-title":"The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences","volume":"16","author":"Klip","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0360","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.hfc.2008.03.008","article-title":"Epidemiology of chronic kidney disease in heart failure","volume":"4","author":"Ahmed","year":"2008","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0365","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2215\/CJN.06020612","article-title":"A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study","volume":"8","author":"Bansal","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0370","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2017.1394833","article-title":"Iron deficiency beyond erythropoiesis: should we be concerned?","volume":"34","author":"Musallam","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0375","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to tango: regulation of mammalian iron metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0380","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jacc.2011.01.059","article-title":"Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure","volume":"58","author":"Maeder","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2011.08.006","article-title":"Myocardial iron homeostasis in advanced chronic heart failure patients","volume":"159","author":"Leszek","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0390","first-page":"362","article-title":"Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure","volume":"38","author":"Haddad","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0395","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis","volume":"19","author":"Melenovsky","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0400","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.celrep.2015.09.023","article-title":"Lethal cardiomyopathy in mice lacking transferrin receptor in the heart","volume":"13","author":"Xu","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0405","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0410","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125618","article-title":"Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity","volume":"4","author":"Chung","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0415","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nefro.2017.03.027","article-title":"Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy","volume":"37","author":"Cases Amen\u00f3s","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0420","doi-asserted-by":"crossref","DOI":"10.3390\/biom8030060","article-title":"Adverse outcome prediction of iron deficiency in patients with acute coronary syndrome","volume":"8","author":"Zeller","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0425","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/jcsm.12314","article-title":"Iron deficiency as energetic insult to skeletal muscle in chronic diseases","volume":"9","author":"Dziegala","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0430","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004800","article-title":"Skeletal muscle abnormalities and iron deficiency in chronic heart failure an exercise 31P magnetic resonance spectroscopy study of calf muscle","volume":"11","author":"Melenovsky","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0435","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","article-title":"Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency: the FERRIC-HF II randomized mechanistic trial","volume":"139","author":"Charles-Edwards","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0440","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/682217","article-title":"Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency","volume":"5","author":"Ruiter","year":"2015","journal-title":"Pulm Circ"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094217","article-title":"Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women\u2014PREFER a randomized, placebo-controlled study","volume":"9","author":"Favrat","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0450","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019240","article-title":"Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials","volume":"8","author":"Houston","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0455","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2891-9-4","article-title":"The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis","volume":"9","author":"Falkingham","year":"2010","journal-title":"Nutr J"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0460","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.sleep.2014.05.009","article-title":"Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom Disease)","volume":"15","author":"Earley","year":"2014","journal-title":"Sleep Med"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0465","article-title":"Iron for the treatment of restless legs syndrome","volume":"1","author":"Trotti","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10266","key":"10.1016\/j.nefroe.2020.11.011_bib0470","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2020.11.011_bib0475","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/TCRM.S25882","article-title":"Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice","volume":"7","author":"Bhandari","year":"2011","journal-title":"Ther Clin Risk Manag"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251421000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:45:46Z","timestamp":1761853546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251421000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2013251421000341"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2020.11.011","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2020.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2020.11.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}